| Literature DB >> 30891508 |
Jingjun Mo1, Shuwen Wang1, Wan Zhang1, Chunyu Li1, Zixin Deng1, Lixin Zhang2, Xudong Qu1.
Abstract
Actinobacteria able to produce varieties of bioactive natural products have been long appreciated by the field of drug discovery and development. Recently, a few of CRISPR/Cas9 systems bearing different types of replicons (pSG5 and pIJ101) were developed to efficiently edit their genomes. Despite wide application in gene editing, their utility in editing challenging DNA regions e.g. high sequence identity has not been compared. In this study, we confirmed that the widely used temperature-sensitive pSG5 replicon is indeed not suitable for editing modular polyketide synthase (PKS) genes due to causing unpredicted gene recombination. This problem can be addressed by replacing the pSG5 with the segregationally unstable pIJ101 replicon. By introducing a counter-selection marker CodA, convenient cloning sites in the single guide RNAs (sgRNAs) and homologous template scaffolds, we developed a new CRISPR-Cas9 system pMWCas9. This system was successfully used to delete/replace erythromycin PKS and other biosynthetic genes in Saccharopolyspora erythraea and Streptomyces sp. AL2110. By swapping the promoters of antB and antC with ermE and kasOp, we achieved a deacyl-antimycin hyper producer which produces a 9-fold higher yield than the original Streptomyces sp. AL2110 strain. Our results provide a robust and useful Cas9 tool for genetic studies in Actinobacteria.Entities:
Keywords: Actinobacteria; Antimycin; Biosynthesis; CRISPR/Cas9; Polyketide synthase
Year: 2019 PMID: 30891508 PMCID: PMC6403111 DOI: 10.1016/j.synbio.2019.02.004
Source DB: PubMed Journal: Synth Syst Biotechnol ISSN: 2405-805X
Fig. 1Editing the erythromycin biosynthetic genes in (A) Deleting the PKS gene eryAIII by pZW-2 and PCR evaluation of its deletion with the wild type HL3168 E3 and plasmid controls. The DSB region is indicated by a break. (B) Analysis of erythromycin production in the mWHU2484 and HL3168 E3 by LC-HRMS. Standard erythromycin (I), HL3168 E3 (II) and mWHU2484 (III). Erythromycin was indicated by selected ion chromatograms. (C) Deleting the PKS gene eryAIII by pWHU2654 (pMWCas9 derivative) and PCR evaluation of its deletion with the wild type HL3168 E3 control. The DSB region in eryAIII is indicated by a break.
Fig. 2The Cas9 vector pMWCas9 (GenBank accession number: MH683611). (A) Cloning strategy of sgRNA. The original two nucleotides AG (shaded) of the sgRNA scaffold were changed into GT in order to introduce a unique XbaI site. The sticky ends generated by EcoRI and XbaI digestion (X/E) can be ligated with the annealed double stranded synthetic oligonucleotides to form the functional sgRNA. N20 is the target sequence should be 3 bp upstream of a PAM sequence. (B) Map of pMWCas9, the backbone is a segregationally unstable pIJ101 replicon, cas9 is controlled by the thiostrepton inducible tipA promoter, the sgRNA cassette is under control of the permE* promoter, apramycin (aac(3)-IV) and codA serve as the selection and counter-selection markers, respectively. The unique cloning sites StuI, SpeI, HpaI and HindIII are for insertion of the homologous template sequence. This plasmid can shuttle between E. coli and Actinomycetes.
Fig. 3Engineering the promotors of (A) Schematic illustration of promoters engineering in the antimycin gene cluster. Constitutive promoters permE* and kasOp were introduced by pMWCas9 to replace the promoters of antB and antC which are responsible for the transcription of antA (antB has been deleted in AL2110) and antC to antE respectively. (B) Deacyl antimycins (DA-1-5 and DA-10, see Fig. S6) productions in the engineered strain mWHU2487 (I) and wild type AL2110 (II). (C) The production yield of deacyl antimycins in pmWHU2478 and AL2110 during the fermentation period (D2-D5). At the D5, mWHU2487 produces deacyl antimycins (62 mg/L) ∼9 fold higher than AL2110 (6.4 mg/L).